This article was originally published here
J Diabetes Sci Technol. 2021 March 5: 1932296821997923. doi: 10.1177 / 1932296821997923. Online before printing.
Diabetes is a growing public health problem and insulin is the mainstay for treating type 1 diabetes. In the treatment of type 2 diabetes, insulin therapy is used after oral or other injectables are no longer sufficient to control blood sugar levels. Despite advances in insulin therapy, treating diabetes remains challenging. Numerous studies have reported low adherence and persistence to insulin therapy, which is an obstacle to successful blood sugar control and diabetes management. The aim of this targeted review article is to provide an overview of the adherence and persistence of insulin therapy in people with diabetes and to discuss the effects of the emergence of a new networked ecosystem of increasingly sophisticated insulin pens, glucose monitoring systems, telemedicine and mHealth on diabetes management. With the advent of a connected diabetes ecosystem, we have entered an era of advanced personalized insulin delivery that has the potential to improve diabetes self-management and clinical management. Early systems promise to unlock the potential to eliminate missed or late bolus insulin delivery, which should help resolve non-compliance and non-persistence. Over time, improvements in this ecosystem can combine insulin data with previously missing contextualized patient data, including meal, glucose, and activity data, to support personalized clinical decisions and ultimately revolutionize insulin therapy.
PMID: 33666097 | DOI: 10.1177 / 1932296821997923